Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endosc… (NCT07027267) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Safety and Effectiveness of TurbAlign™ for Middle Turbinate Medialization After Functional Endoscopic Sinus Surgery
United States50 participantsStarted 2025-08-04
Plain-language summary
A study of a bioabsorbable implant to separate the middle turbinate from the lateral nasal wall associated with nasal/sinus surgery
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ≥18 to ≤ 75 years of age at time of consent
* Subject scheduled to undergo bilateral endoscopic sinus surgery
* Willing and able to provide informed consent and comply with the study protocol
Exclusion Criteria:
* History of removal of one or both middle turbinates
* Presence of significant concha bullosa, which requires surgical excision
* Presence of non-viable tissue at the implantation site
* Active infection at the implantation site
* Chronic nasal decongestant use (i.e. Afrin, etc)
* Recreational intra-nasal drug use within 12 months of enrollment
* Documented evidence of a history (e.g., liver testing) of drug/alcohol abuse within 12 months of enrollment
* Hypersensitivity to any investigational device materials including known or suspected allergy to poly(dioxanone) (PDO) or other bioabsorbable materials